Cordlife assures continuity of operations amidst possible licence suspension
Unaudited 1H2025 results support the company’s outlook.
Cordlife Group Limited said it will be able to continue as a going concern for at least the next 12 months, even if its Ministry of Health (MOH) licence is suspended.
The company’s board said a detailed assessment, including cash flow forecasts up to 30 September 2026, shows Cordlife can maintain operations based on its current financial position and liquidity.
Cordlife added that its unaudited first-half 2025 results support this view.
However, the Board cautioned that there are still “significant uncertainties” and no assurance that the company will not face challenges ahead.
MOH had earlier notified Cordlife of its intention to suspend the company’s cord blood banking and human tissue banking licence for one year, following investigations into temperature issues affecting several cryogenic storage tanks.
If the suspension proceeds, Cordlife will continue to face fixed and operating costs despite a halt in business. The company may also face refunds, possible customer claims, and regulatory penalties.
Cordlife said it will keep monitoring its financial position and update shareholders on any material developments.